Get to know our clinical trials
Clinical trial of linvoseltamab in asymptomatic multiple myeloma patients at high risk of progression to multiple myeloma.
THE OBJECTIVE OF THE STUDY IS TO UNDERSTAND THE SAFETY AND TOLERABILITY (HOW YOUR BODY REACTS TO LINVOSELTAMAB) AS WELL AS THE EFFICACY (TO WHAT EXTENT LINVOSELTAMAB ELIMINATES PLASMA CELLS AND PREVENTS THE DEVELOPMENT OF MM) OF THE STUDY DRUG.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II STUDY OF LINVOSELTAMAB IN PATIENTS WITH ASYMPTOMATIC MULTIPLE MYELOMA AT HIGH RISK OF PROGRESSION TO MULTIPLE MYELOMA
- Code EudraCT: 2023-503524-11-00
- Protocol number: R5458-ONC-2256
- Promoter: Regeneron Pharmaceuticals, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.